natgillin/translations-raw huggingface dataset:
The set of at least two nucleic acid molecules of claim 9, wherein said spacer nucleic acid sequence is at least 17 kb. A cell comprising the recombinant molecule of claim 5 . 
Rekombinantna molekula ili skup od barem dvije molekule nukleinske kiseline prema bilo kojem zahtjevu od 4-6, naznačena time da je navedena molekula ili navedene barem dvije molekule nukleinske kiseline su linearne.
R10, R11 represent, independently from each other, a group selected from hydrogen, C1-C3-alkyl-, benzyl, or 
R'%, R' predstavljaju, međusobno neovisno, skupinu koja je odabrana od vodika, C,-C;-alkila-, benzila, ili
A method of culturing heterologous protein-secreting mammalian cells in a cell culture supernatant wherein the cell culture supernatant is maintained at a pH that is set at X±0.05 wherein X has a value of from 7.15 to 7.20, with the proviso that the pH is set at greater than 7.10, wherein the cell culture is a continuous culture maintained at a density of 1.4x106 to 2.8x106 cells/ml. 
Postupak uzgoja sisavačkih stanica koje izlučuju heterologni protein u supernatantu kulture stanica, naznačen time što se supernatant kulture stanica održava na temperaturi podešenoj na 36 ± 0,9 °C, gdje je kultura stanica kontinuirana kultura, koju se održava uz gustoću od 1,4 × 106 do 2,8 × 106 stanica/ml, te gdje je sisavačka stanica stanica CHO.
According to this third variant, the said polyalkylene glycol polymer is preferentially a polyethylene glycol, a polypropylene glycol, or an ethylene-propylene glycol copolymer, whether random or block. 
Postupak prema zahtjevu 6, naznačen time da navedeni polimer polialkilen glikola je polietilen glikol, polipropilen glikol, ili kopolimer etilen-propilen glikola, bilo statistički kopolimer ili blok kopolimer.
The fan assembly of claim 1, wherein the said axis is substantially vertical when the base is located on a horizontal surface. 
Ventilatorski sustav prema zahtjevu 1, gdje je os oko koje se pokreće propeler (54) u biti okomita kada se baza (12) nalazi na vodoravnoj površini.
The method of item 22, wherein the infectious disease caused by human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), human cytomegalovirus (HCMV), hepatitis C, papillomavirus, Plasmodium, Kaposi's sarcoma associated herpesvirus, Varicella zoster virus, Ebola virus, Mycobacterium tuberculosis, Chikungunya virus, dengue virus, monkeypox virus, herpes simplex 1, herpes simplex 2, Epstein-Barr virus (EBV), poliovirus, influenza virus, or Clostridium tetani. EXAMPLES 
Rekombinantni vektor RhCMY ili HCMY ili pripravak u skladu s patentnim zahtjevom 13, naznačen time što zaraznu bolest uzrokuje virus humane imunodeficijencije (HIV), virus majmunske imunodeficijencije (SIV), ljudski citomegalovirus (HCMV), hepatitis C, papilomavirus, plazmodij, herpesvirus povezan s Kaposijevim sarkomom, virus varicela-zoster, virus ebole, Mycobacterium tuberculosis, virus Chikungunya, virus denge, virus majmunskih boginja, herpes simpleks 1, herpes simpleks 2, Epstein-Barrov virus (EBV), poliovirus, virus influence ili Clostridium tetani.
The terminal apparatus according to one of claims 1-5, wherein when one cluster is allocated, the resource allocation information is signaled using the available bits only; and the determining section determines the resource allocation information based on the available bits. 
Uređaj za prijenos prema jednom od zahtjeva 1 do 5, naznačen time da kad se dodjeljuje jedan klaster, podatak o dodjeli resursa signalizira se korištenjem dostupnih bitova u polju dodjele resursa isključivo.
Acetylcholine (10 ug/kg) was injected intravenously in every 10 minutes for 60 min. 
Acetilkolin (10 ug/kg) je injektiran intravenozno svakih 10 minuta tijekom 60 min.
The pharmaceutical composition of claim 1, wherein the effective amount of bifeprunox mesylate is 5 mg. 
Farmaceutski sastav prema zahtjevu 1, naznačen time da učinkovita količina bifeprunoks mesilata iznosi 5 mg.
Many variations and/or adaptations may be applied by the man of skill in the art to the temperature, the overpressure, the circulation loop flow and the duration for/at which steps (b) to (d) are carried out. 
Puno varijacija i/ili adaptacija se mogu primijeniti od strane stručnjaka, a koje se odnose na temperaturu, tlak, kružni cirkulacijski protok i vremensko razdoblja za korake od (b) pa do (d).
The use of the present light stabilising composition in an effective amount to inhibit light induced flavour changes is evident by a reduction in the rate of 3-MBT formation by at least 30%, preferably by at least 50%, more preferably by at least 60%, even more preferably by at least 70% and most preferably by at least 80%. 
Upotreba sadašnjeg pripravka za stabiliziranje na svjetlo u djelotvornoj količini za inhibiranje promjena arome induciranih svjetlom je očita smanjenjem brzine stvaranja 3-MBT za najmanje 30%, poželjno za najmanje 50%, poželjnije za najmanje 60%, čak još poželjnije za najmanje 70% i najpoželjnije za najmanje 80%.
(c2) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 9; 
(c2) L-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 9;
is selected from the group consisting of and R5; 
G' je odabran iz skupine koju čine i R';
A peptide mixture, a T-cell mixture or a pharmaceutical composition for use according to claim 10, wherein the cancer is colorectal, lung and/or pancreatic cancer. A peptide mixture, a T-cell mixture or a pharmaceutical composition for use in a method of treatment said method comprising: identifying RAS protein mutations present in a sample taken from a patient; 
Peptidna smjesa, smjesa T stanica, ili farmaceutska kompozicija za primjenu u skladu sa patentnim zahtjevom 6, gdje navedena profilaksa i/ili liječenje sadrži identificiranje aminokiselinskih supstitucija RAS proteina prisutnih u uzorku uzetom od pacijenta.
A device according to claim 2 characterised in that said microfluidic channels (6a, 6b) are capillary channels, wherein the surfaces of said channels are hydrophilic and capillarity acts as the only force for moving the fluid medium. 
Mikrofluidički uređaj u skladu s patentnim zahtjevom 2, naznačen time što navedeni mikrofluidički kanali (6a, 6b) su kapilarni kanali, gdje površine navedenih kanala su hidrofilne, a kapilarnost je jedina pogonska sila za fluidni medij.
a transform unit (120) configured to transform a residual block to generate a transform block; a quantization unit (130) configured to quantize the transform block to generate a quantized block; a scanning unit (131) configured to scan coefficients of the quantized block using a scan pattern determined according to the intra prediction mode; and 
dekoder rezidualnog signala (220) konfiguriran za vraćanje rezidualnog signala pomoću intrapredikcijskog režima; generator referentnih piksela (240) konfiguriran za generiranje referentnih piksela koji odgovaraju nedostupnim referentnim pikselima i za adaptivno filtriranje referentnih piksela u skladu s intrapredikcijskim režimom; generator predikcijskog bloka (250) konfiguriran za generiranje predikcijskih piksela pomoću referentnih piksela određenih intrapredikcijskim režimom;
The reaction stirred an additional 21 hours then was worked up by filtering the sieves from the reaction solution, diluting the filtrate with EtOAc and washing with water. 
Reakcijska smjesa je bila miješana dodatnih 21 sat, zatim je bila dorađena filtriranjem sita iz otopine reakcijske smjese, razrjeđivanjem filtrata s EtOAc i ispiranjem vodom.
The method of any one of claims 1-8, wherein the nucleic acid is introduced into the plant in a transient manner or wherein the nucleic acid is stably integrated within a genome of the plant. 
Postupak sukladno patentnom zahtjevu 1, naznačen time, da se nukiemska kiselina uvodi u biljku na prijelazni način ili gdje je nuklemska kiselma stabilno integrirana unutar genoma biljke.
• applying the wood fibres and the uncured binder for the sub layer on the core, 
• primjenu drvenih vlakana (14) i nestvrdnutog veziva (19) kao praha za podsloj na jezgri (6);
After stirring for 20 min (2-bromoethoxy)- t- butyldimethylsilane (7.03g, 6.31 mL, 29.4 mmol) was added dropwise over 20 min at 0 °C then the reaction heated to 70 °C for 3.5 h. On cooling to room temperature the reaction was quenched by careful addition of water (2 mL) then the volatiles evaporated. 
Nakon 20 minuta miješanja (2-brometoksi)-t- butildimetilsilan (7,03g, 6,31 ml, 29,4 mmol) se ukapava 20 minuta na 0 "C, a zatim se reakcijsku smjesu grije 3,5 sati na 70 "C. Nakon hlađenja na sobnu temperaturu rcakcijsku smjesu se ugasi pažljivim dodavanjem vode (2 ml), a hlapiveo tvari otpari.
The anti-IL-13 antibody of claim 8 wherein said anti-IL-13 antibody comprises complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively. The anti-IL-13 antibody of claim 8, wherein said anti-IL-13 antibody comprises a variable light chain region and a variable heavy chain region and wherein the variable light chain region comprises the amino acid sequence set forth in SEQ ID NO: 142 and a variable heavy chain region comprises the amino acid sequence set forth in SEQ ID NO: 143. 
VL područje lanca, koje sadrži aminokiselinski slijed s formulom: FRL1-CDRL1-FRL2-CDRL2FRL3-CDRL3-FRL4, gdje se FRL1 sastoji od bilo kojeg od SEQ ID NO: 20 do 25; CDRL1 se sastoji od bilo kojeg od SEQ ID NO: 99 do 103; FRL2 se sastoji od SEQ ID NO: 29; CDRL2 se sastoji od bilo kojeg od SEQ ID NO: 104 do 114; FRL3 se sastoji od bilo kojeg od SEQ ID NO: 30 do 56; CDRL3 se sastoji od bilo kojeg od SEQ ID NO: 115 do 116; i FRL4 se sastoji od bilo kojeg od SEQ ID NO: 57 do 59; i
Further said dry ball-shaped surface modified calcium carbonate containing mineral, has a median grain diameter of from 4 um to about 100 um, preferably from about 5 um to about 75 um, more preferably from about 10 um to about 50 um, still more preferably from about 15 um to about 30 um. FIG. 
Površinski modificirani kalcijev karbonat koji sadrži mineral prema zahtjevu 21, naznačen time da površinski modificirani kalcijev karbonat koji sadrži mineral ima medijan promjera zrna od 4 um do oko 100 um, poželjno od oko 5 um do oko 75 um, poželjnije od oko 10 um do oko 50 um, još poželjnije od oko 15 um do oko 30 um, određeno s uređajem Malvern Mastersizer.
In the illustrated embodiment, the metered dose valve 2 comprises a spring 15 for biasing the valve element 5 in the first or upper position as shown in FIG. 1 . 
U prikazanoj izvedbi, ventil za odmjeravanje doze 2 obuhvaća oprugu 15 za prenaprezanje elementa ventila 5 u prvi ili gornji položaj, kako je prikazano na slici 1.
represents a hydrogen atom, an oxo group, a alkyl group optionally substituted by 1 to 3 halogen atoms, or a C1-6 alkoxy group optionally substituted by 1 to 3 halogen atoms, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom. 
predstavlja vodikov atom, okso skupinu, skupinu C1-6 alkil proizvoljno supstituiranu s 1 do 3 halogenih atoma, ili skupinu C1-6 alkoksi proizvoljno supstituiranu s 1 do 3 halogenih atoma, uz uvjet da kada E predstavlja azetidinski prsten i R2 ili R3 je prisutan na dušikovom atomu na azetidinskom prstenu, R2 ili R3 ne predstavljaju vodikov atom.
In yet another further embodiment, for the compound according to formula (I) Q is S. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj formule (I) spoj formule (IA):
A combination according to claim 3 or 4, wherein the B2 agonist is selected from the group comprising formoterol, salmeterol and QAB-149 optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija u skladu s patentnim zahtjevom 3, naznačena time, da je inhibitor PDE4 odabran iz skupine koju čine cilomilast, roflumilast, denbufilin i tetomilast, po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina.
The composition used in the present invention further comprises usually as a component c) at least one physiologically acceptable carrier, preferably a solvent. 
Pripravak koji se koristi u ovom izumu nadalje obično obuhvaća kao sastojak c) barem jedan fiziološki prihvatljiv nosač, poželjno otapalo.
A method according to claim 1, wherein the eukaryotic cell is a yeast cell. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu je eukariotska stanica stanica kvasca.
A method for the preparation of the agomelatine hydrochloride hydrate according to claim 1 or 2, wherein agomelatine is dissolved in organic solvent before aqueous HCl solution is added to precipitate the crystal of the product. 
Postupak za pripremu agomelatina hidroklorid hidrata u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da se agomelatin otopi u organskom otapalu prije dodavanja vodene otopine HCI da se istaloži kristal proizvoda.
An isolated, recombinant, mutagenized, or synthetic sunflower acetohydroxyacid synthase large subunit (AHASL) polynucleotide, wherein said AHASL polynucleotide encodes an imidazolinone herbicide-tolerant AHASL1 protein comprising a threonine or another amino acid other than alanine at amino acid position 107 or an equivalent position relative to the amino acid sequence set forth in SEQ ID NO:12, wherein said AHASL1 protein confers upon a plant increased tolerance to an imidazolinone herbicide as compared to a wild-type variety of said plant. 
Biljka suncokreta, naznačena time, da u svojem genomu sadrži barem jednu kopiju od barem jednog endogenog gena koji sadrži veliku podjedinicu polinukleotida sinteze acetohidroksilne kiseline (AHASL), gdje spomenuti AHASL polinukleotid kodira imidazolinon AHASL1 protein otporan na herbicide, koji sadrži sekvencu amino kiseline iznesenu u SEQ ID NO:2; ili njezina biljka potomak, pri čemu spomenuta biljka suncokreta ili njezin potomak, ima povećanu otpornost na barem jedan imidazolinonski herbicid u usporedbi s divljim tipom biljke suncokreta.
The device according to claim 1, wherein said surface of said body of permanent-magnetic material carrying the indicia in the form of engravings is covered with a non-magnetic material. 
Uređaj sukladno jednom od patentnih zahtjeva 1 do 3, naznačen time, da je navedena površina pokrivena nemagnetskim materijalom, a taj materijal poželjno ispunjava navedene gravure u navedenom tijelu.
The topical veterinary composition of clause 13, wherein the insect growth regulator is (S)-methoprene, pyriproxyfen, hydroprene, cyromazine, fluazuron, lufenuron, or novaluron. 
Topikalni veterinarski pripravak prema zahtjevu 10, naznačen time, da je regulator rasta kukaca (S)-metopren, piriproksifen, hidropren, ciromazin, fluazuron, lufenuron ili novaluron.
A therapeutic agent for treating or reducing a disease including injury to central nervous system, such as head trauma and spinal cord injury, cerebral infarction, ischemic heart diseases and peripheral arterial occlusive diseases, or after-effects of these diseases, by promoting axonal outgrowth or promoting angiogenesis, the therapeutic agent containing a compound represented by the above described formula (I-aa), or a pharmaceutically acceptable salt thereof, as an active ingredient. 
Sredstvo za poticanje aksonskog izrastanja i/ili poticanje angiogeneze ili terapeutsko sredstvo za liječenje ili smanjenje bolesti uključujući ozljede središnjeg živčanog sustava, kao što su trauma glave 1 ozljeda leđne moždine, moždani infarkt, ishemijske bolesti srca i bolesti začepljenja perifernih arterija, ili posljedica navedenih bolesti, pomoću poticanja aksonskog izrastanja i/ili poticanja angiogeneze, naznačen time da kao aktivni sastojak sadrži spoj prema zahtjevima 1 do 4, ili njegovu farmaceutski prihvatljivu sol.
The pharmaceutical combination composition of claim 3, wherein the second therapeutic agent is selected from the group consisting of Ampicillin, Piperacillin, Penicillin G, Ticarcillin, Imipenem, Meropenem, Azithromycin, Erythromycin, Aztreonam, Cefepime, Cefotaxime, Ceftriaxone, Ceftazidime, Ciprofloxacin, Levofloxacin, Clindamycin, Doxycycline, Gentamycin, Amikacin, Tobramycin, Tetracycline, Tigecycline, Rifampicin, Vancomycin and Polymyxin. 
Farmaceutska kombinacija u skladu s patentnim zahtjevom 10, pri čemu je drugo terapeutsko sredstvo odabrano iz skupine koja se sastoji od ampicilina, piperacilina, penicilina G, tikarcilina, imipenema, meropenema, azitromicina, eritromicina, aztreonama, cefepima, cefotaksima, ceftriaksona, ceftazidima, ciprofloksacina, levofloksacina, klindamicina, doksiciklina, gentamicina, amikacina, tobramicina, tetraciklina, tigeciklina, rifampicina, vankomicina i polimiksina.
A compound or salt according to claim 1, wherein R1 is heteroaryl substituted with C1-C3 alkyl. 
Spoj ili sol u skladu s patentnim zahtjevom 1, naznačen time što je R1 heteroaril, supstituiran s C1-C3 alkilom.
The method as recited in claim 16, wherein the coating material is cured for 5 to 90 min. at a temperature of from 80 to 110° C. The method as recited in claim 16, further comprising: 
Postupak prema zahtjevu 12 ili 13, naznačen time, da se obložni materijali učvršćuju/suše u vremenu od 5 do 90 minuta na temperaturi od 80 do 110*C.
This demonstrates the linearity of the pharmacokinetics of levofloxacin after single and multiple aerosol doses of levofloxacin with the 100 mg/ml formulation. 
Aerosol za uporabu sukladno bilo kojem od patentnih zahtjeva 1 do 5, pri čemu je koncentracija levofloksacina ili ofloksacina 100 mg/ml.
Use of a cell that has been genetically modified to produce an IL-18BP according to claim 1 or 2 for the manufacture of a medicament for the treatment and/or prevention of a disease selected from: tumor metastasis, psoriasis, arthritis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, liver injury, atherosclerosis, sepsis, myocardial infarction, traumatic brain injury, allergy, peripheral vascular disease, multiple sclerosis. 
Uporaba stanice koja je genetski modificirana za dobivanje IL-18BP prema zahtjevu 1 ili 2 naznačena time da je za proizvodnju lijeka za liječenje i/ili sprečavanje bolcsti koje su odabrane od: metastaze tumora, psorijaze, artritisa, reumatoidnog artritisa, upalne bolesti crijeva, Crohnove bolesti, oštećenja jetre, ateroskleroze, sepse, infarkta miokarda, traumatskih oštećenja mozga, alergije, periferne vaskularne bolesti, multiple skleroze.
the water-insoluble film-forming polymer P 1 is chosen from the group consisting of water-insoluble cellulose derivatives, the water-soluble polymer P 2 is chosen from group consisting of polyvinylpyrrolidone (PVP); soluble cellulose derivatives; isomalt; maltodextrin; poloxamers; polyethylene glycol; polyvinyl alcohol; vinylpyrrolidone-vinyl acetate copolymer; xanthan gum; acacia gum; carragheenan gum; guar gum; carob gum; agar-agar; polydextrose; methylvinyl ether and maleic anhydride or maleic acid copolymers; and mixtures thereof; and 
u vodi topljivi polimer P2 izabire se iz grupe koja obuhvaća polivinilpirolidon (PVP); topljive derivate celuloze, kao hidroksipropilmetil celulozu (HPMC), metilcelulozu, hidroksietil celulozu, hidroksietilmetil celulozu, hidroksipropilcelulozu, natrij karboksimetil celulozu; izomalt; maltodekstrin; poloksamere; polietilen glikol; polivinil alkohol; vinilpirolidon-vinil acetat kopolimer; ksantan gumu; akacija gumu; karagenan gumu; guar gumu; karob gumu; agar-agar; polidekstrozu; metilvinil eter i maleinski anhidrid ili kopolimere maleinske kiseline; i njihove smjese, taj polimer je poželjno polivinilpirolidon; i
To further illustrate without limiting the invention, the pain disorder to be treated is selected from the group consisting of fibromyalgia syndrome (FMS), overall pain, back pain, shoulder pain, headache as well as pain while awake and during daily activities. 
Kako bi dalje ilustrirali bez da izum ograničimo, smetnje bola koje treba tretirati biraju se iz grupe koja se sastoji od sindroma fibromijalgije (FMS), općih bolova, bolova u leđima, ramenu, glavobolja kao I bolova u budnom stanju I tijekom dnevnih aktivnosti.
The method of claim 5, wherein the base is potassium t-botoxide. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što baza je kalijev f-butoksid.
IL-18BP is not the extracellular domain of one of the known IL-18 receptors, but a secreted, naturally circulating protein. 
1L-18BP nije vanstanična domena nekog od poznatih receptora za IL-18, već protein koji se izlučuje i prirodno nalazi u cirkulaciji.
The data were fitted with non-linear regression, and IC50 and Ki values were calculated from the equations: EPMATHMARKEREP and EPMATHMARKEREP where [I] is the inhibitor concentration, [ag] is the assay agonist concentration and EC50 is the agonist concentration required for half maximal effect. 
Ki = ICs0/1-[ag]'EC:s9), gdje je [IT] koncentracija inhibitora, [ag] koncentracijski agonist koji se ispituje i ECs5, koncentracijski agonist koji je propisan za polovicu od ukupne učinkovitosti. Ispitivanje A», vezanja:
a first polyol, the first polyol being selected from mannitol, sorbitol or a combination thereof, the concentration of the first polyol being at least 0.01 w/v% but no greater than 0.5 w/v%; 
prvi poliol, te je prvi poliol odabran od manitola, sorbitola ili njihove kombinacije, pri čemu je koncentracija prvog poliola najmanje 0,01 m/v% ali manja od 0,5 m/v%;
The compound for use according to claim 10 further comprising administering one or two additional compounds having anti-HCV activity prior to, after or simultaneously with the compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 42 koji dalje obuhvaća uporabu jednog ili dva dodatna spoja s djelovanjem protiv HCV-a prije, nakon ili istodobno sa spojem prema zahtjevu 1, ili njegovom farmaceutski prihvatljivom soli.
The process of compounding of the elastomer of this invention is standard in the art of elastomer manufacture, and numerous competent organisations are known which are capable of manufacturing such an elastomer and the appropriate colourant masterbatches. 
Postupak miješanja elastomera koji se koristi u ovom izumu je standardan u struci koja se bavi proizvodnjom elastomera i poznate su brojne kompetenine organizacije koje mogu proizvoditi takav elastomer i odgovarajuće glavne šarže sa sredstvom za bojenje.
A problem exists in trying to make sure that any attachment strap closely underlies or follows the contours of parts of the inhaler near the nozzle when the material of the strap is plastic without sufficient elastic flexibility to stretch so as to pull tight against the inhaler. 
Problem se javlja želimo li postići da dodana vrpca tijesno slijedi oblik dijelova inhalatora koji su blizu kljuna ako je materijal od kojega je načinjena vrpca plastika bez dovoljno elastičnosti da se istegne i tijesno nalegne uz inhalator.
A pharmaceutical composition for preventing or treating a disease associated with 17BHSD type 5, comprising the compound according to claim 1 or a salt thereof. 
Uporaba spoja prema zahtjevu 1 ili njegove soli, naznačena time, da je za proizvodnju farmaceutskog sastava za prevenciju ili liječenje bolesti povezane s 17BHSD tip 5.
In an alternative embodiment of the invention there is provided a flow control device in which the faces of the prism are concave. 
Uređaj za kontrolu protoka (1) u skladu s patentnim zahtjevom 3 ili 4, naznačen time što su stranice prizme konkavne.